NEW YORK (GenomeWeb) – Sunnyvale, California-based firm InSilixa is developing an assay to test for hundreds of potential targets that confer drug resistance to Mycobacterium tuberculosis.

The TB test is intended to showcase the firm's core technology, which can perform highly multiplexed nucleic acid amplification and analysis of hundreds of targets simultaneously.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.